CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 16, Pages 3982
Publisher
MDPI AG
Online
2021-08-09
DOI
10.3390/cancers13163982
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy
- (2021) E.C. Smyth et al. ANNALS OF ONCOLOGY
- CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer
- (2021) Nataliia Petruk et al. Scientific Reports
- CD73 promotes tumor metastasis by modulating RICS/RhoA signaling and EMT in gastric cancer
- (2020) Zhijun Xu et al. Cell Death & Disease
- CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer
- (2020) Qiangda Chen et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
- (2020) Takashi Kojima et al. JOURNAL OF CLINICAL ONCOLOGY
- CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis
- (2019) Xiao-Lu Ma et al. Journal of Hematology & Oncology
- Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies
- (2019) Ivan Perrot et al. Cell Reports
- Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
- (2019) Selena Vigano et al. Frontiers in Immunology
- Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML
- (2019) Janus S. Jakobsen et al. Science Advances
- CD73: an emerging checkpoint for cancer immunotherapy
- (2019) Siqi Chen et al. Immunotherapy
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
- (2018) Xiaolei Li et al. Journal of Hematology & Oncology
- CD73 expression and clinical significance in human metastatic melanoma
- (2018) Inês Monteiro et al. Oncotarget
- Targeting adenosine for cancer immunotherapy
- (2018) Robert D. Leone et al. Journal for ImmunoTherapy of Cancer
- Necroptosis microenvironment directs lineage commitment in liver cancer
- (2018) Marco Seehawer et al. NATURE
- Esophageal squamous cell carcinoma and prognosis in Taiwan
- (2018) Ya-Fu Cheng et al. Cancer Medicine
- EMT: 2016
- (2016) M. Angela Nieto et al. CELL
- Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action
- (2016) James C. Geoghegan et al. mAbs
- Purinergic Signaling During Immune Cell Trafficking
- (2016) Davide Ferrari et al. TRENDS IN IMMUNOLOGY
- CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
- (2015) Martin Turcotte et al. CANCER RESEARCH
- CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
- (2015) B. G. Leclerc et al. CLINICAL CANCER RESEARCH
- Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
- (2015) Paul A. Beavis et al. Cancer Immunology Research
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- The Roles of CD73 in Cancer
- (2014) Zhao-wei Gao et al. Biomed Research International
- Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
- (2013) B. Allard et al. CLINICAL CANCER RESEARCH
- Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil
- (2013) Zhengdeng Lei et al. GASTROENTEROLOGY
- Anti-CD73 therapy impairs tumor angiogenesis
- (2013) Bertrand Allard et al. INTERNATIONAL JOURNAL OF CANCER
- CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
- (2013) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Purinergic signalling and cancer
- (2013) Geoffrey Burnstock et al. Purinergic Signalling
- Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma
- (2013) Xiao-Xia Lu WORLD JOURNAL OF GASTROENTEROLOGY
- CD73-Deficient Mice Are Resistant to Carcinogenesis
- (2012) J. Stagg et al. CANCER RESEARCH
- High expression of CD73 as a poor prognostic biomarker in human colorectal cancer
- (2012) Xian-Rui Wu et al. JOURNAL OF SURGICAL ONCOLOGY
- CD73: a potent suppressor of antitumor immune responses
- (2012) Paul. A. Beavis et al. TRENDS IN IMMUNOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice
- (2011) Long Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Extracellular adenosine triphosphate and adenosine in cancer
- (2010) J Stagg et al. ONCOGENE
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started